PHILIP F STAHEL, MD
Medical Practice at Bannock St, Denver, CO
License number
Colorado 43456
Category
Medical Practice
Type
Orthopaedic Trauma
Address
Address
777 Bannock St, Denver, CO 80204
Phone
(303) 436-6000
Personal information
See more information about PHILIP F STAHEL at radaris.comName
Address
Phone
330 Cherry St, Denver, CO 80220
Denver, CO
330 Cherry St, Denver, CO 80220
Professional information
See more information about PHILIP F STAHEL at trustoria.com
Philip F Stahel, Denver CO
Philip F Stahel, Denver CO
Specialties:
Neurological Surgery, Orthopaedic Surgery, Orthopaedic Surgery of the Spine, Orthopaedic Trauma, Surgery
Work:
Center For Complex Fractures & Limb Restoration - Pavilion B
780 Delaware St, Denver, CO 80204
780 Delaware St, Denver, CO 80204
Dr. Philip F Stahel - MD (Doctor of Medicine)
Dr. Philip F Stahel - MD (Doctor of Medicine)
Hospitals:
777 Bannock St, Denver 80204
Denver Health Medical Center
777 Bannock St, Denver 80204
777 Bannock St, Denver 80204
Denver Health Medical Center
777 Bannock St, Denver 80204
Denver Health Medical Center
777 Bannock St, Denver 80204
777 Bannock St, Denver 80204
Denver Health Medical Center
777 Bannock St, Denver 80204
Inhibition Of Factor B And The Alternative Complement Pathway For Treatment Of Traumatic Brain Injury And Related Conditions
Inhibition Of Factor B And The Alternative Complement Pathway For Treatment Of Traumatic Brain Injury And Related Conditions
US Patent:
2006029, Dec 28, 2006
Filed:
May 26, 2006
Appl. No.:
11/441828
Inventors:
Vernon Holers - Denver CO, US
Joshua Thurman - Greenwood Village CO, US
Stephen Tomlinson - Mount Pleasant SC, US
Philip Stahel - Denver CO, US
Joshua Thurman - Greenwood Village CO, US
Stephen Tomlinson - Mount Pleasant SC, US
Philip Stahel - Denver CO, US
Assignee:
The Regents of the University of Colorado - Boulder CO
MUSC Foundation for Research Development - Charleston SC
MUSC Foundation for Research Development - Charleston SC
International Classification:
A61K 39/395
US Classification:
424144100
Abstract:
Disclosed is the use of agents and compositions that selectively inhibit the alternative complement pathway for the inhibiting or treating physiological damage resulting from traumatic brain injury (TBI), spinal cord injury (SCI), or related conditions. Preferred reagents for use in inhibition of damage resulting from TBI or SCI include those that inhibit factor B, with anti-factor B antibodies representing a particularly preferred agent.